Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Imunon, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ENROLLMENT MOMENTUM EXCEEDING EXPECTATIONS IS BASED ON HIGHLY PROMISING SURVIVAL (OS) DATA AND WELL TOLERATED SAFETY PROFILE DEMONSTRATED IN THE COMPANY'S LARGE, RANDOMIZED PHASE II STUDY, OVATION 2 STRONG ENROLLMENT DEMONSTRATES THE CONFIDENCE OF PRINCIPAL INVESTIGATORS FROM PRESTIGIOUS CANCER INSTITUTIONS IN THE TRIAL DESIGN AND ITS POTENTIAL FOR A SUCCESSFUL OUTCOME ENROLLMENT AHEAD OF PLAN ACROSS ALL STUDY SITES. ADDITIONAL SITES OPENING ON PACE WITH PROJECTIONS LAWRENCEVILLE, N.J.

IMUNON REPORTS STRONG ENROLLMENT MOMENTUM IN PHASE 3 OVATION 3 TRIAL OF IMNN-001 IN ADVANCED OVARIAN CANCER

TRANSLATIONAL AND CLINICAL DATA REINFORCE IMNN-001'S POTENTIAL TO UNLOCK IL-12'S ANTI-TUMOR POWER IN OVARIAN CANCER WITHIN A HIGHLY SAFE, PROPRIETARY MECHANISM

IMUNON TO PRESENT IMNN-001 DATA AT INAUGURAL AACR CONFERENCE ON DRUG DISCOVERY AND DEVELOPMENT

PRELIMINARY DATA REINFORCES IMNN-001 IMMUNOTHERAPY'S POTENTIAL FOR SUCCESS IN THE RAPIDLY RECRUITING PHASE 3 OVATION 3 CLINICAL TRIAL LOWER RATE OF MINIMAL RESIDUAL DISEASE (MRD)HIGHER CTDNA CLEARANCE WITH IMNN-001 VS. CONTROLHIGHLY FAVORABLE SAFETY AND TOLERABILITY PROFILE STUDY, CONDUCTED IN PARTNERSHIP WITH BREAK THROUGH CANCER, PROVIDES NEW TRANSLATIONAL DATA AND FURTHER SUPPORT FOR IMNN-001'S UNIQUE MECHANISM OF REMODELING THE TUMOR IMMUNE MICROENVIRONMENT LAWRENCEVILLE, N.

IMUNON REPORTS POSITIVE PHASE 2 MRD CLINICAL DATA FOR IMNN-001, DEMONSTRATING THE SUCCESSFUL OVERCOMING OF HISTORICAL IL-12 SAFETY BARRIERS IN FRONTLINE OVARIAN CANCER

ON TRACK FOR ENROLLMENT OF 80 PARTICIPANTS BY Q1 2027 TRIAL IS SUPPORTED BY PHASE 2 RESULTS SHOWING SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER NOVEL IMMUNOTHERAPY TECHNOLOGY DEMONSTRATING UNPRECEDENTED IL-12 SAFETY PROFILE AND EXTRAORDINARY PHASE 2 EFFICACY LAWRENCEVILLE, N.J., JUNE 23, 2026 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC) HAS RECOMMENDED CONTINUATION OF THE PIVOTAL PHASE 3 OVATION 3 CLINICAL TRIAL EVALUATING IMNN-001 IN COMBINATION WITH STANDARD OF CARE (SOC) NEOADJUVANT AND ADJUVANT CHEMOTHERAPY (N/ACT) IN WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER.

IMUNON ANNOUNCES DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF PHASE 3 OVATION 3 STUDY WITHOUT MODIFICATION

LAWRENCEVILLE, N. J. , JUNE 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT STACY LINDBORG, PH. D.

IMUNON TO PRESENT AT THE LIFE SCIENCES INVESTOR FORUM ON JUNE 25TH

INCLUDES UP-FRONT ISSUANCE OF PREFERRED STOCK FOR $2.5 MILLION AND SECUREDPROMISSORY NOTES FOR $7.72 MILLION UNIQUELY STRUCTURED, FLEXIBLE FINANCING SUPPORTS IMUNON'S HIGHLY ANTICIPATED PHASE 3 OVATION 3 STUDY OF IMNN-001 IN ADVANCED OVARIAN CANCER LAWRENCEVILLE, N.J., JUNE 04, 2026 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT THE COMPANY HAS ENTERED INTO DEFINITIVE AGREEMENTS WITH EXPECTED AGGREGATE GROSS PROCEEDS TO THE COMPANY IN THE AMOUNT OF $10 MILLION.

IMUNON ANNOUNCES UP TO $10 MILLION CASH FINANCING

IMNN-001 IS THE FIRST AND ONLY FRONTLINE TREATMENT CANDIDATE TO DEMONSTRATE THE POTENTIAL FOR A CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT IN WOMEN NEWLY DIAGNOSED WITH OVARIAN CANCER ENROLLMENT IN THE PHASE 3 OVATION 3 STUDY OF IMNN-001 IS EXPECTED TO BE COMPLETED BY Q1 2029, SUPPORTED BY REMARKABLE PHASE 2 DATA SHOWING SIGNIFICANT OVERALL SURVIVAL IMPROVEMENT FDA HAS REVIEWED AND IS ALIGNED WITH PHASE 3 PROTOCOL, CONFIRMS PATH TO BLA FILING COMPANY TO HOLD CONFERENCE CALL TODAY AT 11:00 A.M. ET LAWRENCEVILLE, N.J.

IMUNON REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

LAWRENCEVILLE, N.J., MAY 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN LATE-STAGE DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, ANNOUNCES THAT THE COMPANY WILL HOST A CONFERENCE CALL AT 11:00 A.M.

IMUNON TO HOLD FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATE CONFERENCE CALL ON TUESDAY, MAY 12, 2026

IMNN-001 IS THE FIRST FRONTLINE IMMUNOTHERAPY TO DEMONSTRATE THE POTENTIAL FOR A CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT IN WOMEN NEWLY DIAGNOSED WITH ADVANCED OVARIAN CANCER FINAL PHASE 2 CLINICAL DATA SHOW CONTINUED MEDIAN OVERALL SURVIVAL IMPROVEMENT WITH IMNN-001 ENROLLMENT IN THE OVATION 3 STUDY, IMUNON'S PHASE 3 PIVOTAL TRIAL FOR IMNN-001, REMAINS AHEAD OF PLAN SUPPORTED BY CONTINUED STRONG INTEREST FROM PRINCIPAL INVESTIGATORS AND THE MEDICAL COMMUNITY COMPANY TO HOLD CONFERENCE CALL TODAY AT 11:00 A.M. EDT LAWRENCEVILLE, N.J.

IMUNON REPORTS 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE HIGHLIGHTING SIGNIFICANT PROGRESS WITH PIVOTAL PHASE 3 STUDY

THE INCREASE IN MEDIAN OVERALL SURVIVAL AMONG WOMEN TREATED WITH IMNN-001 IN THE OVATION 2 TRIAL ROSE FROM THE PREVIOUSLY REPORTED 11.1 MONTHS TO 14.7 MONTHS FOLLOWING FINAL DATA ANALYSIS PATIENTS TREATED WITH PARP INHIBITOR THERAPY IN ADDITION TO IMNN-001 AND STANDARD OF CARE CHEMOTHERAPY DEMONSTRATED MEDIAN INCREASE IN OS OF 24.2 MONTHS ENROLLMENT IN IMUNON'S PHASE 3 PIVOTAL TRIAL FOR IMNN-001 REMAINS AHEAD OF PLAN, SUPPORTED BY CONTINUED STRONG INTEREST FROM INVESTIGATORS AND MEDICAL COMMUNITY LAWRENCEVILLE, N.J., MARCH 25, 2026 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED FINAL CLINICAL DATA FROM THE COMPLETED PHASE 2 OVATION 2 CLINICAL TRIAL EVALUATING IMNN-001 IN COMBINATION WITH STANDARD OF CARE (SOC) NEOADJUVANT AND ADJUVANT CHEMOTHERAPY (N/ACT).

IMUNON REPORTS UPDATED PHASE 2 DATA SHOWING CONTINUED IMPROVEMENT IN MEDIAN OVERALL SURVIVAL WITH IMNN-001 IN WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER

Imunon, Inc.

IMNN

Price

Financial Reports

No items found.

Press Releases

Imunon, Inc.

IMNN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMNN